Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
1.730
-0.030 (-1.70%)
At close: Dec 5, 2025, 4:00 PM EST
1.720
-0.010 (-0.58%)
After-hours: Dec 5, 2025, 7:57 PM EST
Cognition Therapeutics Employees
As of December 31, 2024, Cognition Therapeutics had 28 total employees, including 25 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
28
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$999,500
Market Cap
152.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | 0 | - |
| Dec 31, 2023 | 28 | 3 | 12.00% |
| Dec 31, 2022 | 25 | 4 | 19.05% |
| Dec 31, 2021 | 21 | 1 | 5.00% |
| Dec 31, 2020 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CGTX News
- 5 days ago - Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 15 days ago - Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 23 days ago - Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease - GlobeNewsWire
- 4 weeks ago - Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs - GlobeNewsWire
- 3 months ago - Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target - GlobeNewsWire
- 3 months ago - These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 - The Motley Fool
- 3 months ago - Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) - GlobeNewsWire
- 3 months ago - Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock - GlobeNewsWire